Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
about
JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.Ruxolitinib-associated infections: A systematic review and meta-analysis.SOHO State-of-the-Art Update and Next Questions: MPN.Ruxolitinib for essential thrombocythemia?Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia.Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018.Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors
P2860
Q48109284-2E2D01D2-3880-4A57-8D13-5A59861169EAQ48278553-69F77E5F-8670-429B-A1A9-80C3789C9B6AQ49580473-AAA91604-F7BF-4DA1-9075-74C497CACEE2Q49727337-E44D91E8-69D7-4CD9-9E7D-75540364AC90Q49887981-1164A763-BE69-42BF-A364-F5A0AD7AE8B3Q52668513-66E0D160-0289-4FA1-9703-54F83A6DCA28Q55386134-42F4A6E4-4AA8-47B1-A848-4319575A9C08Q58801187-F622056F-B789-4C28-846E-2D97A5BE31E8
P2860
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
@en
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
@nl
type
label
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
@en
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
@nl
prefLabel
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
@en
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
@nl
P2093
P50
P1433
P1476
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide
@en
P2093
Aimee Houlton
Anesh Panchal
Angela Hamblin
Claire N Harrison
Emmanouela Gbandi
Frederick Chen
Jason Coppell
Joanne Ewing
Marion Wood
Mary Frances McMullin
P304
P356
10.1182/BLOOD-2017-05-785790
P407
P577
2017-08-09T00:00:00Z